The effect of menopause on metabolic syndrome: cross-sectional results from the Canadian Longitudinal Study on Aging
- PMID: 32852451
- DOI: 10.1097/GME.0000000000001575
The effect of menopause on metabolic syndrome: cross-sectional results from the Canadian Longitudinal Study on Aging
Abstract
Objectives: Data were examined from women surveyed in the Canadian Longitudinal Study on Aging to evaluate whether menopause is an independent risk factor for the development of metabolic syndrome (MetS) or its components, including hypertension, central obesity, dyslipidemia, or elevated glycated hemoglobin.
Methods: We conducted a cross-sectional analysis of women aged 45-85 years old that participated in the baseline data of the Canadian Longitudinal Study on Aging Comprehensive Cohort collected from 2012 to 2015. Modified Poisson regression with robust error variance was used to estimate the crude and adjusted relative risks (aRRs) of MetS in postmenopausal women compared to premenopausal women.
Results: Among 12,611 women analyzed, 10,035 (79.6%) had undergone menopause and 2,576 (20.4%) were premenopausal. Postmenopausal women were more likely to meet criteria for MetS compared to premenopausal women (32.6% vs 20.5%, P < 0.001). Using the MetS criteria with a lower waist circumference threshold, the prevalence of MetS was higher at 38.2% among postmenopausal women and 23.2% among premenopausal women (P < 0.001). After adjusting for age, body mass index, and other covariates, the occurrence of menopause was not associated with a significantly higher relative risk of MetS, using the unified criteria for MetS (aRR 1.09 [95% CI: 0.99-1.19]). Women with menopause had a significantly higher relative risk of MetS when using criteria with a lower waist circumference (aRR 1.10 [95% CI: 1.01-1.19]). Menopause was also associated with a higher risk of impaired glucose tolerance (aRR 1.42 [95% CI: 1.26-1.59]), elevated blood pressure (aRR 1.12 [95% CI: 1.03-1.21]), and elevated triglycerides (aRR 1.17 [95% CI: 1.08-1.26]).
Conclusion: Menopause is associated with an increased risk of MetS, independent of age. Lifestyle interventions targeted at women with MetS are known to prevent type 2 diabetes mellitus and cardiovascular risk. Perimenopause may be an important preventative care opportunity to assess metabolic risk factors and improve health and longevity of Canadian women.
Comment in
-
What drives metabolic syndrome after menopause, and can we do anything about it?Menopause. 2020 Sep;27(9):972-973. doi: 10.1097/GME.0000000000001610. Menopause. 2020. PMID: 32852447 No abstract available.
References
-
- Kaaja RJ. Metabolic syndrome and the menopause. Menopause Int 2008; 14:2125.
-
- Statistics Canada. Metabolic syndrome in adults, 2012 to 2013. Available at: https://www.statcan.gc.ca/pub/82-625-x/2014001/article/14123-eng.htm. Published 2015. Accessed January 1, 2018.
-
- Statistics Canada. Health Statistics Division. The 10 Leading Causes of Death, 2013. 2017. Available at: https://www.statcan.gc.ca/pub/82-625-x/2017001/article/14776-eng.htm. Accessed January 1, 2018.
-
- Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death. A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403414.
-
- Rosato V, Bosetti C, Talamini R, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011; 22:26872692.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical